Pharmaxis Signs Agreement with Boehringer Ingelheim for SSAO Inhibitor PXS4728A
12th
Mar 15
Release Date: 12/03/2015 12:00am
Pharmaceutical company Pharmaxis (ASX: PXS) today announced it has signed an Option and Asset Purchase Agreement with Boehringer Ingelheim International GmbH(Boehringer) for the Pharmaxis Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor PXS4728A.
Categories: News and Media